A detailed history of Black Rock Inc. transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 227,406 shares of ALGS stock, worth $4.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
227,406
Previous 303,755 25.14%
Holding current value
$4.3 Million
Previous $297,000 73.4%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.35 - $1.07 $26,722 - $81,693
-76,349 Reduced 25.14%
227,406 $79,000
Q1 2024

May 10, 2024

BUY
$0.64 - $1.13 $4,874 - $8,606
7,616 Added 2.57%
303,755 $297,000
Q4 2023

Feb 13, 2024

SELL
$0.56 - $0.8 $459 - $656
-820 Reduced 0.28%
296,139 $195,000
Q3 2023

Nov 13, 2023

SELL
$0.71 - $1.06 $2,487 - $3,714
-3,504 Reduced 1.17%
296,959 $222,000
Q2 2023

Aug 11, 2023

SELL
$0.89 - $1.36 $6,352 - $9,707
-7,138 Reduced 2.32%
300,463 $291,000
Q1 2023

May 12, 2023

BUY
$0.87 - $2.11 $132 - $320
152 Added 0.05%
307,601 $267,000
Q4 2022

Feb 13, 2023

SELL
$0.89 - $28.0 $186,997 - $5.88 Million
-210,110 Reduced 40.6%
307,449 $292,000
Q3 2022

Nov 14, 2022

SELL
$1.06 - $27.5 $8,476 - $219,917
-7,997 Reduced 1.52%
517,559 $569,000
Q2 2022

Aug 12, 2022

SELL
$1.04 - $2.14 $1.12 Million - $2.3 Million
-1,075,462 Reduced 67.17%
525,556 $636,000
Q1 2022

May 12, 2022

BUY
$2.08 - $12.2 $5,647 - $33,123
2,715 Added 0.17%
1,601,018 $3.44 Million
Q4 2021

Feb 10, 2022

BUY
$11.48 - $17.69 $4.12 Million - $6.35 Million
358,741 Added 28.94%
1,598,303 $19 Million
Q3 2021

Nov 09, 2021

BUY
$14.57 - $17.72 $2.27 Million - $2.76 Million
155,518 Added 14.35%
1,239,562 $19.2 Million
Q2 2021

Aug 11, 2021

BUY
$20.3 - $33.6 $22 Million - $36.4 Million
1,084,044 New
1,084,044 $22.1 Million

Others Institutions Holding ALGS

# of Institutions
3
Shares Held
253K
Call Options Held
0
Put Options Held
0

About Aligos Therapeutics, Inc.


  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $751M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.